摘要
目的观察紫杉醇单药治疗老年非小细胞肺癌(NSCLC)的近期疗效及毒副反应,评价其治疗老年NSCLC的安全性。方法 48例经病理或细胞学确诊的老年NSCLC患者。采用紫杉醇135 mg/m2,静脉滴注3 h,d1,21 d为1周期,所有患者均接受2个疗程化疗。结果 48例患者均可评价疗效及毒副反应。部分缓解(PR)19例(39.6%),稳定(SD)23例(47.9%),进展(PD)6例(12.5%),(PR+SD)42例(87.5%)。主要不良反应有骨髓抑制,恶心和呕吐,肌痛和关节痛,脱发,肝功能异常,多为Ⅰ～Ⅱ度反应。结论紫杉醇单药治疗老年(≥65岁)NSCLC疗效较好,毒性低,患者耐受性良好,值得在临床上推广使用。
Objective To explore the efficacy and toxicity of paclitaxel alone in treatment of elderly non-small-cell lung carcinoma（NSCLC）.Methods Forty-eight patients aged ≥65 years were definitely diagnosed as NSCLC by histology.All patients were intravenously administrated with 135 mg/m2 paclitaxel for 3 h d1,repeated every 21 days.All patients received two courses of treatment.Results The therapeutic efficacy of 48 patients were evaluated.There were 19 cases of partial remission（39.6%）,23 cases of SD（47.9%）,6 cases of PD（12.5%） and 42 cases of PR＋SD,and the total effective rate（PR＋SD） was 87.5%.The side effects included bone marrow suppression,nausea and vomiting,myalgia,arthritis,alopecia and so on.Conclusion The treatment with paclitaxel alone showed good therapeutic efficacy and low toxicity in elderly patients with NSCLC.
出处
《中国肿瘤临床与康复》
2011年第2期154-156,共3页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
紫杉醇
肺肿瘤/化学疗法
老年
Paclitaxel
Lung neoplasms/chemotherapy
Elder1y
作者简介
权蓉，女，学士，副主任医师，从事肿瘤临床专业。
